Skip to main content
. 2023 Feb 8;7(21):6532–6539. doi: 10.1182/bloodadvances.2022009381

Figure 3.

Figure 3.

Cause of treatment failure after HSCT for relapsed or refractory ML-DS. Cumulative incidence of subsequent relapse and treatment-related mortality.